Search - tctmd.com

Displaying 1 - 20 of 69

Sort: Relevancy | Date

Presentation TCT 2016

Multicenter Global Registry Report of the Two-year Outcomes with a Paclitaxel-Coated Balloon in Patients with Complex Femoropopliteal Lesions

Presenter: Thomas F. Luscher, Patrick W. Serruys, D. Christopher Metzger

October 31, 2016

Presentation

Paclitaxel-Coated Balloon in Infrapopliteal Arteries

Presenter: Thomas Zeller

October 23, 2015

Presentation

Late Restenosis After Paclitaxel-Coated Balloon Angioplasty in Patients With DES Restenosis

Presenter: Seiji Habara

June 30, 2015

Presentation

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Presenter: Kenneth Rosenfield

June 25, 2015

Presentation

Long-term Efficacy and Safety of Paclitaxel-Eluting Balloon (PEB) for the Treatment of DES Restenosis

Presenter: Sebastian Kufner

June 02, 2015

Presentation

Paclitaxel-Coated Balloon Catheter Compared With DES for DES Restenosis in Routine Clinical Practice

Presenter: S Habara

March 01, 2015

Presentation

Stent Coverage and Neointimal Proliferation in BMS Postdilated With a Paclitaxel-Eluting Balloon vs EES

Presenter: T.C. Poerner

December 14, 2014

Presentation TCT 2014

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Freek Nijhoff

September 16, 2014

Presentation TCT 2014

Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use of Drug Coated Balloon Catheters

Presenter: Charisse Ward

September 16, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

Presentation TCT 2014

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

Presenter: Run-Lin Gao, Jochen Wöhrle, Bruno Scheller, Yelin Zhao

September 13, 2014

Presentation EuroPCR 2014

Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results

Presenter: Hiroyoshi Yokoi

May 21, 2014

Presentation EuroPCR 2014

BABILON TRIAL: A prospective randomized study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions

Presenter: Jos? Ram?n L?pez-M?nguez

May 20, 2014

Presentation TCT 2013

Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development

Presenter: Michael Joner

October 31, 2013

Presentation TCT 2013

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

Presenter: Kenneth Rosenfield

October 30, 2013

Presentation TCT 2013

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

Presenter: Fernando Alfonso

October 30, 2013

Presentation TCT 2013

TCT-38. Three-year clinical data of the BIOSOLVE-I Study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS) and multi-modality imaging analysis

Presenter: Michael Haude

October 29, 2013

Presentation TCT 2013

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Presenter: Peter Smits

October 29, 2013

Presentation TCT 2013

TCT-56. PEPCAD China ISR: A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon versus Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis ...

Presenter: Bo Xu

October 29, 2013

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

Advertisement

Multicenter Global Registry Report of the Two-year Outcomes with a Paclitaxel-Coated Balloon in Patients with Complex Femoropopliteal Lesions

Paclitaxel-Coated Balloon in Infrapopliteal Arteries

Late Restenosis After Paclitaxel-Coated Balloon Angioplasty in Patients With DES Restenosis

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Long-term Efficacy and Safety of Paclitaxel-Eluting Balloon (PEB) for the Treatment of DES Restenosis

Paclitaxel-Coated Balloon Catheter Compared With DES for DES Restenosis in Routine Clinical Practice

Stent Coverage and Neointimal Proliferation in BMS Postdilated With a Paclitaxel-Eluting Balloon vs EES

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use of Drug Coated Balloon Catheters

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results

BABILON TRIAL: A prospective randomized study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions

Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

TCT-38. Three-year clinical data of the BIOSOLVE-I Study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS) and multi-modality imaging analysis

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

TCT-56. PEPCAD China ISR: A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon versus Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis ...

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content